Advanced Track · 3 of 5

Half-Life Engineering

Lipidation, albumin-hitchhiking, PEGylation and DAC — the real magic behind weekly drugs

The core problem

Natural peptides are usually cleared from the body in minutes. Native GLP-1's half-life is roughly 2 minutes — the enzyme DPP-4 chops it up almost immediately.1 A drug you'd have to inject every few minutes is useless. The entire modern peptide-drug industry is, in a sense, the science of making short-lived peptides last.

The toolkit

native peptide (t½ ≈ 2 min)cleared fast (DPP-4)+ fatty-acid chain → binds albumin (t½ days)albuminprotected → weekly dosing
A fatty-acid chain lets a peptide hitch onto albumin, hiding it from clearance — the trick that turns a 2-minute molecule into a once-weekly drug.

Why 'No-DAC' vs 'DAC' matters

Read the suffix: the same core peptide with an albumin-binding group can go from short-acting to multi-day. "No-DAC" isn't a weaker version — it's a different kinetics profile. Recognizing modifications (DAC, acylation, PEG) tells you how often something is meant to act and how long it lingers.

The lesson

When you see a peptide marketed as "long-acting" or "weekly," ask what modification makes it so. The mechanism (the receptor) tells you what it does; the half-life engineering tells you how long and how often.

Further reading — primary sources

  1. Peptide half-life extension — lipidation, albumin binding, PEGylation (review). ACS Med. Chem. Lett.
  2. Peptide Therapeutics 2.0 — review. PMC7287585

Apply it → browse the 75-compound library

For educational and research purposes only. This content is not medical advice. Compounds referenced are research use only unless noted as approved drugs, and nothing here is an instruction to use, prepare, or administer anything. Free Peptide University does not sell compounds.